How effective is ustekinumab for Crohn's disease?

In the treatment of Crohn's disease, ustekinumab (administered by infusion) was compared with placebo in 2 major studies involving 1369 patients with moderately to severely active disease. The primary measure of effectiveness will be the number of patients whose symptom scores improve 6 weeks after infusion. In the first study, symptom scores improved in approximately 34% of patients who received ustekinumab, compared with 21% of patients who received placebo. In the second study, the figure was 56% for ustekinumab and 29% for placebo. 2Some patients in the main study received ustekinumab (subcutaneous injection) or placebo every 8 or 12 weeks. After initiating treatment by subcutaneous injection for 44 weeks, 53% of patients receiving ustekinumab every 8 weeks n>49%of patients who received ustekinumab at week 12 had a significant reduction in Crohn's disease symptoms, compared with 36% of patients in the placebo group. If you want to get more high-quality information, you can contact Yaode, and Yaode will do its best to help you learn more about high-quality overseas drugs.